Integrium selects phase forward irt for enhanced clinical trial supply management


Specialized CRO Selects Phase Forward’s Interactive Response Technology Solution
to Help Ensure Optimal Supply Availability

WALTHAM, Mass. – April 6, 2010 – Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Integrium LLC, a contract research organization (CRO) specializing in dermatology, cardiovascular and metabolic disease clinical research, recently signed an agreement for the use of Phase Forward™ IRT.

Integrium works with specialty, development-stage, mid-size, and large biopharmaceutical and medical device companies, providing a complete range of clinical trial management services for Phase I through Phase IV dermatology, cardiovascular and metabolic disease studies. Integrium is headquartered in Tustin, Calif., with operational offices in Bedminster, N.J. and Johannesburg, South Africa.

The Integrium team implemented Phase Forward IRT because of its cutting-edge technology, rapid deployment and streamlined workflow to support advanced clinical trial planning and management, according to Integrium. Total cost of ownership was also a key consideration.

“A strong technology strategy is critical to overall success and cost efficiency in clinical drug and device development,” said Eileen McAuley, Chief Operating Officer, Integrium LLC. “We implemented Phase Forward IRT because we were impressed by the capabilities of the technology, Phase Forward’s reputation as a market leader, and the potential to adopt additional products within the company’s suite as our needs evolve over time.”

“Integrium has developed a strong reputation for expertise and excellence in dermatology, cardiovascular and metabolic disease clinical trials,” said Scott Dixon, Vice President, Global CRO Partnerships, Phase Forward. “We look forward to working with the Integrium team to help deliver the consistent, high-quality results that sponsors count on from the company.”

Phase Forward’s CRO partnership strategy is designed to assist CRO clients in achieving success in both the short and long term. Its customized structure and flexible pricing options help CROs of all sizes to invest in their own capabilities and capitalize on new growth opportunities.

About Integrium, LLC

Integrium is a therapeutically-focused, full-service contract research organization that specializes in dermatology, cardiovascular and metabolic clinical research. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) methodology and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at